Drug Profile
Research programme: HDL-related therapeutics - Esperion/Cleveland Clinic
Alternative Names: 4 WF; Apolipoprotein A1-4 WFLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Esperion Therapeutics; The Cleveland Clinic Foundation
- Developer Cleveland Clinic; Esperion Therapeutics
- Class Peptides; Small molecules
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute coronary syndromes; Dyslipidaemias
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Acute coronary syndromes in USA (Parenteral)
- 23 Feb 2023 Discontinued - Preclinical for Dyslipidaemias in USA (PO)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Acute coronary syndromes in USA (Parenteral, Injection)